Seal Rock Therapeutics
Seal Rock Therapeutics is a clinical-stage biotechnology company dedicated to advancing medicine through breakthrough science. They focus on developing first-in-class and best-in-class kinase inhibitors to treat severe diseases such as liver and neurodegenerative diseases, with a mission to address unmet medical needs. Their leadership team has extensive experience in drug discovery, development, and commercialization, and they are committed to pioneering therapies for conditions with limited treatment options.
Industries
Nr. of Employees
small (1-50)
Seal Rock Therapeutics
Patents
Products
SRT-015
A clinical-stage small-molecule ASK1 kinase inhibitor optimized for liver-preferential distribution; developed for treatment of NASH, alcoholic hepatitis and other severe liver diseases. Evaluated in preclinical NASH and cholestatic fibrosis models and advanced into Phase 1 clinical testing.
SRT-055
A preclinical brain-penetrant dual kinase inhibitor series targeting ASK1 and LRRK2 intended for neurodegenerative disease indications such as Parkinson’s disease and ALS; undergoing preclinical characterization and funded studies.
SRT-015
A clinical-stage small-molecule ASK1 kinase inhibitor optimized for liver-preferential distribution; developed for treatment of NASH, alcoholic hepatitis and other severe liver diseases. Evaluated in preclinical NASH and cholestatic fibrosis models and advanced into Phase 1 clinical testing.
SRT-055
A preclinical brain-penetrant dual kinase inhibitor series targeting ASK1 and LRRK2 intended for neurodegenerative disease indications such as Parkinson’s disease and ALS; undergoing preclinical characterization and funded studies.
Services
Collaborative research relationships to advance preclinical drug discovery and development for liver and neurodegenerative diseases, including shared studies and program partnerships.
Structuring out-licensing or partnership agreements for development and commercialization of alternative formulations (for example, injectable formulation development by a partner).
Execution of IND-enabling packages including toxicology, pharmacology, PK/PD and CMC work to support regulatory filings.
Program and project management services focused on clinical development planning, clinical operations execution and clinical data management.
Collaborative research relationships to advance preclinical drug discovery and development for liver and neurodegenerative diseases, including shared studies and program partnerships.
Structuring out-licensing or partnership agreements for development and commercialization of alternative formulations (for example, injectable formulation development by a partner).
Execution of IND-enabling packages including toxicology, pharmacology, PK/PD and CMC work to support regulatory filings.
Program and project management services focused on clinical development planning, clinical operations execution and clinical data management.
Expertise Areas
- Kinase inhibitor drug discovery
- Medicinal chemistry and small-molecule synthesis
- Preclinical pharmacology and efficacy testing
- Translational medicine and biomarker-driven development
Key Technologies
- Kinase inhibition (ASK1, LRRK2)
- Liver-targeted small-molecule design
- Brain-penetrant small-molecule design
- In vivo disease models (DIO-NASH, cholestatic fibrosis)
News & Updates
Seal Rock Therapeutics will present preclinical data on SRT-015 for severe cholestatic disease during a poster presentation at the EASL Congress 2024 in Milan, Italy. The data demonstrate the ability of SRT-015 to significantly decrease fibrosis in a model of cholestatic disease with severe fibrosis, supporting its potential as a therapeutic treatment.
Seal Rock Therapeutics entered into an out-licensing agreement with GENFIT for the development of an injectable formulation of SRT-015 for ACLF, with potential payments up to €100 million including milestone payments and royalties.
Seal Rock Therapeutics received a SBIR grant from NIH to support preclinical evaluation of SRT-015 as a potential therapy for acute alcoholic hepatitis.
Seal Rock Therapeutics was awarded a $547,000 grant from USAMRAA to support preclinical evaluation of SRT-055 for ALS.
Seal Rock Therapeutics announced that SRT-055 shows promise in lab studies for Parkinson's disease.
Seal Rock announced promising preclinical findings for SRT-015, a liver-selective ASK1 inhibitor for NASH, with ongoing IND-enabling activities.
Seal Rock Therapeutics will present preclinical data on SRT-015 for severe cholestatic disease during a poster presentation at the EASL Congress 2024 in Milan, Italy. The data demonstrate the ability of SRT-015 to significantly decrease fibrosis in a model of cholestatic disease with severe fibrosis, supporting its potential as a therapeutic treatment.
Seal Rock Therapeutics entered into an out-licensing agreement with GENFIT for the development of an injectable formulation of SRT-015 for ACLF, with potential payments up to €100 million including milestone payments and royalties.
Seal Rock Therapeutics received a SBIR grant from NIH to support preclinical evaluation of SRT-015 as a potential therapy for acute alcoholic hepatitis.
Seal Rock Therapeutics was awarded a $547,000 grant from USAMRAA to support preclinical evaluation of SRT-055 for ALS.
Seal Rock Therapeutics announced that SRT-055 shows promise in lab studies for Parkinson's disease.
Seal Rock announced promising preclinical findings for SRT-015, a liver-selective ASK1 inhibitor for NASH, with ongoing IND-enabling activities.